Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
35 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Achieve Life Sciences, Inc.’s names, not what it holds today.
Patents granted
35
35 utility, 1976 to Dec 31, 2025
Granted in 2025
1
in the last year the record reads
Applications published
29
2 of them in 2025
Names they are printed under
3
a former name, its own name
By yearGrantedApplications published
'99'00'01'02'03'04'05'06'07'08'10'21'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
Measurement1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Sonus Pharmaceuticals, Inc. a former name
US, as the owner printed on each patent
22 publishedAchieve Life Sciences, Inc. its own name
named as the applicant on its applications, in US
7 publishedAchieve Life Sciences, Inc. its own name
US, as the owner printed on each patent
0 publishedNames not counted (1)
ONCOGENEX PHARMACEUTICALS, INC.
Most of its patents print CA; this name counts in US. 0 granted and 1 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Sep 23, 2025 | 12,422,415 | Analytical methods of assessing cytisine purity | Measurement | Achieve Life Sciences, Inc. |
| Aug 10, 2021 | 11,083,716 | Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof | Pharmaceuticals | Achieve Life Sciences, Inc. |
| Aug 10, 2021 | 11,083,715 | Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof | Pharmaceuticals | Achieve Life Sciences, Inc. |
| Aug 31, 2010 | 7,786,164 | Lipophilic di(anticancer drug) compounds, compositions, and related methods | Pharmaceuticals | Sonus Pharmaceuticals, Inc. |
| Aug 31, 2010 | 7,786,134 | Lipophilic anticancer drug compounds, compositions and related methods | Organic fine chemistry | Sonus Pharmaceuticals, Inc. |
| Sep 11, 2007 | 7,268,245 | Multinuclear platinum compounds | Organic fine chemistry | Sonus Pharmaceuticals, Inc. |
| Jun 19, 2007 | 7,232,919 | Platinum compounds | Organic fine chemistry | Sonus Pharmaceuticals, Inc. |
| May 29, 2007 | 7,223,770 | Tocopherol-modified therapeutic drug compounds | Pharmaceuticals | Sonus Pharmaceuticals, Inc. |
| Oct 31, 2006 | 7,129,368 | Platinum carboxylate anticancer compounds | Pharmaceuticals | Sonus Pharmaceuticals, Inc. |
| Aug 15, 2006 | 7,091,374 | Fluorinated compounds | Organic fine chemistry | Sonus Pharmaceuticals, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jun 12, 2025 | 2025/0186417 | CYTISINE FORMULATIONS | Pharmaceuticals | Achieve Life Sciences, Inc. |
| Jun 12, 2025 | 2025/0186416 | SMOKING CESSATION COMPOUNDS HAVING REDUCED NITROSAMINES AND ASSOCIATED METHODS | Pharmaceuticals | Achieve Life Sciences, Inc. |
| Dec 26, 2024 | 2024/0426794 | METHODS OF CONTROL AND ANALYSIS OF N-NITROSOCYTISINE IN CYTISINE SAMPLES | Measurement | Achieve Life Sciences, Inc. |
| Mar 23, 2023 | 2023/0090994 | ANALYTICAL METHODS OF ASSESSING CYTISINE PURITY | Measurement | Achieve Life Sciences, Inc. · patent 12,422,415 granted from it |
| Oct 28, 2021 | 2021/0330652 | COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF | Pharmaceuticals | Achieve Life Sciences, Inc. |
| Mar 18, 2021 | 2021/0077475 | COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF | Pharmaceuticals | Achieve Life Sciences, Inc. · patent 11,083,716 granted from it |
| Mar 18, 2021 | 2021/0077473 | COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF | Pharmaceuticals | Achieve Life Sciences, Inc. · patent 11,083,715 granted from it |
| Feb 21, 2008 | 2008/0045559 | TOCOPHEROL-MODIFIED THERAPEUTIC DRUG COMPOUNDS | Pharmaceuticals | Sonus Pharmaceuticals, Inc. |
| Sep 6, 2007 | 2007/0207196 | TOCOPHEROL-MODIFIED THERAPEUTIC DRUG COMPOUND FORMULATIONS | Pharmaceuticals | Sonus Pharmaceuticals, Inc. |
| Jun 21, 2007 | 2007/0142331 | LIPOPHILIC ANTICANCER DRUG COMPOUNDS, COMPOSITIONS AND RELATED METHODS | Organic fine chemistry | Sonus Pharmaceuticals, Inc. · patent 7,786,134 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 2 · Measurement 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.